Valeant Pharmaceuticals International (VRX)
News
| May 31 | [video] Thursday 5/31 Insider Buying Report: HPQ, VRX |
| May 31 | Thursday 5/31 Insider Buying Report: HPQ, VRX |
| May 31 | What are the Insiders Buying? Fool |
| May 31 | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Submission of Matters... |
| May 30 | $VRX has been a hedge fund favorite for a little while now by marketfolly |
| May 30 | Jeffrey Ubben's ValueAct Capital has bought around 1.5m shares of $VRX over past month (via various SEC Form 4's). Owns 17.1m shares now by marketfolly |
| May 30 | Valeant (VRX) to Syndicate $500M of Incremental Term Loans Street Insider |
| May 30 | Valeant Pharmaceuticals To Syndicate Incremental Term Loans Benzinga |
| May 30 | InPlay: Valeant Pharmaceuticals to syndicate $500 mln of incremental term loans |
| May 29 | Valeant's Acquisition Spree Continues |
| May 24 | $VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 http://stks.co/3yvG #corpgov by corpgovnet |
| May 24 | $VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 New Information #corpgov by corpgovnet |
| May 23 | $VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 50 http://stks.co/3xWY #corpgov #VRX #Valeant by corpgovnet |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Delivery & Accessories
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. The focus of the company is on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of speciality chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. Kinerase, used kinetin as active entity is one of the most famous product of this company. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company is headquartered in Mississauga, Canada.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Valeant Pharmaceuticals International is down 3.72% over the last year vs S&P 500 Total Return down 0.41%, Hospira down 43.05%, and Elan Corporation up 46.03%.
- VRX Total Returns
- ^SPXTR Total Returns
- HSP Total Returns
- ELN Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these VRX related companies
Pro Strategies Featuring VRX
Did Valeant Pharmaceuticals International make it into our Pro Portfolio Strategies?
VRX Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other VRX Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VRX | 48.66 | +0.74 | +1.54% | 14.92B |
| VRTX | 60.04 | -0.14 | -0.23% | 12.63B |
| VRTS | 70.88 | +0.51 | +0.72% | 545.78M |
| VRTB | 1.260 | -0.00 | -0.01% | 16.56M |
| VRTA | 1.10 | -0.04 | -3.51% | 6.974M |
| VRSN | 38.23 | -0.39 | -1.01% | 6.098B |
| VRSK | 47.90 | +0.01 | +0.02% | 7.893B |
| VRS | 1.15 | +0.04 | +3.60% | 60.48M |
| VRNT | 28.72 | -0.32 | -1.10% | 1.116B |
| VRNM | 3.58 | +0.16 | +4.68% | 45.14M |
